drugset / Trial / NCT01753713
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Phase 2
Completed
33 enrolled
Manmeet Ahluwalia, MD
National Cancer Institute (NCI) · collabNovartis · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase II trial studies how well dovitinib works in treating patients with recurrent or progressive glioblastoma. Dovitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Timeline
- Start
- 2012-12-20
- Primary completion
- 2015-01-28
- Completion
- 2017-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dovitinib | Small molecule | — | Oral |